Cargando…

Computational prediction of protein subdomain stability in MYBPC3 enables clinical risk stratification in hypertrophic cardiomyopathy and enhances variant interpretation

PURPOSE: Variants in MYBPC3 causing loss of function are the most common cause of hypertrophic cardiomyopathy (HCM). However, a substantial number of patients carry missense variants of uncertain significance (VUS) in MYBPC3. We hypothesize that a structural-based algorithm, STRUM, which estimates t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thompson, Andrea D., Helms, Adam S., Kannan, Anamika, Yob, Jaime, Lakdawala, Neal K., Wittekind, Samuel G., Pereira, Alexandre C., Jacoby, Daniel L., Colan, Steven D., Ashley, Euan A., Saberi, Sara, Ware, James S., Ingles, Jodie, Semsarian, Christopher, Michels, Michelle, Mazzarotto, Francesco, Olivotto, Iacopo, Ho, Carolyn Y., Day, Sharlene M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group US 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8257482/ https://www.ncbi.nlm.nih.gov/pubmed/33782553 http://dx.doi.org/10.1038/s41436-021-01134-9

Ejemplares similares

Spatial and Functional Distribution of MYBPC3 Pathogenic Variants and Clinical Outcomes in Patients With Hypertrophic Cardiomyopathy
por: Helms, Adam S., et al.
Publicado: (2020)

Hypertrophic Cardiomyopathy With Left Ventricular Systolic Dysfunction: Insights From the SHaRe Registry
por: Marstrand, Peter, et al.
Publicado: (2020)

Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy
por: Marston, Nicholas A, et al.
Publicado: (2021)

Temporal Trend of Age at Diagnosis in Hypertrophic Cardiomyopathy: An Analysis of the International Sarcomeric Human Cardiomyopathy Registry
por: Canepa, Marco, et al.
Publicado: (2020)

Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights From the Sarcomeric Human Cardiomyopathy Registry (SHaRe)
por: Ho, Carolyn Y., et al.
Publicado: (2018)

Left Ventricular Systolic Dysfunction in Patients Diagnosed With Hypertrophic Cardiomyopathy During Childhood: Insights From the SHaRe Registry
por: Abou Alaiwi, Sarah, et al.
Publicado: (2023)

External validation of the HCM Risk-Kids model for predicting sudden cardiac death in childhood hypertrophic cardiomyopathy
por: Norrish, Gabrielle, et al.
Publicado: (2021)

Sex Differences in Hypertrophic Cardiomyopathy: Interaction With Genetics and Environment
por: Butters, Alexandra, et al.
Publicado: (2021)

Quantitative approaches to variant classification increase the yield and precision of genetic testing in Mendelian diseases: the case of hypertrophic cardiomyopathy
por: Walsh, Roddy, et al.
Publicado: (2019)

An Update on MYBPC3 Gene Mutation in Hypertrophic Cardiomyopathy
por: Tudurachi, Bogdan-Sorin, et al.
Publicado: (2023)

Development of a communication aid for explaining hypertrophic cardiomyopathy genetic test results
por: Smagarinsky, Yana, et al.
Publicado: (2017)

Physical activity in hypertrophic cardiomyopathy: prevalence of inactivity and perceived barriers
por: Sweeting, Joanna, et al.
Publicado: (2016)

Evaluating a custom-designed aid to improve communication of genetic results in families with hypertrophic cardiomyopathy: study protocol for a randomised controlled trial
por: Burns, Charlotte, et al.
Publicado: (2019)

INHERIT (INHibition of the renin angiotensin system in hypertrophic cardiomyopathy and the Effect on hypertrophy—a Randomised Intervention Trial with losartan)
por: Olivotto, Iacopo, et al.
Publicado: (2015)

Contemporary Insights Into the Genetics of Hypertrophic Cardiomyopathy: Toward a New Era in Clinical Testing?
por: Mazzarotto, Francesco, et al.
Publicado: (2020)

Adverse events in families with hypertrophic or dilated cardiomyopathy and mutations in the MYBPC3 gene
por: Ehlermann, Philipp, et al.
Publicado: (2008)

Familial hypertrophic cardiomyopathy associated with a new mutation in gene MYBPC3
por: Aurensanz Clemente, Esther, et al.
Publicado: (2017)

Protein haploinsufficiency drivers identify MYBPC3 variants that cause hypertrophic cardiomyopathy
por: Suay-Corredera, Carmen, et al.
Publicado: (2021)

Slower Calcium Handling Balances Faster Cross-Bridge Cycling in Human MYBPC3 HCM
por: Pioner, Josè Manuel, et al.
Publicado: (2023)

Disease-specific variant pathogenicity prediction significantly improves variant interpretation in inherited cardiac conditions
por: Zhang, Xiaolei, et al.
Publicado: (2020)

Transcriptome Analysis of Cardiac Hypertrophic Growth in MYBPC3-Null Mice Suggests Early Responders in Hypertrophic Remodeling
por: Farrell, Emily, et al.
Publicado: (2018)

Myosin Sequestration Regulates Sarcomere Function, Cardiomyocyte Energetics, and Metabolism, Informing the Pathogenesis of Hypertrophic Cardiomyopathy
por: Toepfer, Christopher N., et al.
Publicado: (2020)

Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy
por: Braunwald, Eugene, et al.
Publicado: (2023)

Autosomal Recessive Transmission of MYBPC3 Mutation Results in Malignant Phenotype of Hypertrophic Cardiomyopathy
por: Wang, Yilu, et al.
Publicado: (2013)

The Metabolome in Finnish Carriers of the MYBPC3-Q1061X Mutation for Hypertrophic Cardiomyopathy
por: Jørgenrud, Benedicte, et al.
Publicado: (2015)

Fatal neonatal hypertrophic cardiomyopathy caused by compound heterozygous truncating MYBPC3 mutation
por: Alsters, S., et al.
Publicado: (2019)

Molecular autopsy in victims of inherited arrhythmias
por: Semsarian, Christopher, et al.
Publicado: (2016)

Myocardial Deformation Analysis in MYBPC3 and MYH7 Related Sarcomeric Hypertrophic Cardiomyopathy—The Graz Hypertrophic Cardiomyopathy Registry
por: Höller, Viktoria, et al.
Publicado: (2021)

MYBPC3 mutations are associated with a reduced super-relaxed state in patients with hypertrophic cardiomyopathy
por: McNamara, James W., et al.
Publicado: (2017)

Reevaluation of the South Asian MYBPC3(Δ25bp) Intronic Deletion in Hypertrophic Cardiomyopathy
por: Harper, Andrew R., et al.
Publicado: (2020)

Hypertrophic cardiomyopathy in myosin-binding protein C (MYBPC3) Icelandic founder mutation carriers
por: Adalsteinsdottir, Berglind, et al.
Publicado: (2020)

Identification of an elusive spliceogenic MYBPC3 variant in an otherwise genotype-negative hypertrophic cardiomyopathy pedigree
por: Torrado, Mario, et al.
Publicado: (2022)

Untargeted Metabolomics Identifies Potential Hypertrophic Cardiomyopathy Biomarkers in Carriers of MYBPC3 Founder Variants
por: Jansen, Mark, et al.
Publicado: (2023)

Clinical Phenotype and Outcome of Hypertrophic Cardiomyopathy Associated With Thin-Filament Gene Mutations
por: Coppini, Raffaele, et al.
Publicado: (2014)

Multi-omics integration identifies key upstream regulators of pathomechanisms in hypertrophic cardiomyopathy due to truncating MYBPC3 mutations
por: Pei, J., et al.
Publicado: (2021)

Sex‐Related Differences in Genetic Cardiomyopathies
por: Argirò, Alessia, et al.
Publicado: (2022)

BIO FOr CARE: biomarkers of hypertrophic cardiomyopathy development and progression in carriers of Dutch founder truncating MYBPC3 variants—design and status
por: Jansen, M., et al.
Publicado: (2021)

Repair of Mybpc3 mRNA by 5′-trans-splicing in a Mouse Model of Hypertrophic Cardiomyopathy
por: Mearini, Giulia, et al.
Publicado: (2013)

Combined PTPN11 and MYBPC3 Gene Mutations in an Adult Patient with Noonan Syndrome and Hypertrophic Cardiomyopathy
por: Caiazza, Martina, et al.
Publicado: (2020)

Description of a Cohort with a New Truncating MYBPC3 Variant for Hypertrophic Cardiomyopathy in Northern Spain
por: Fernández Suárez, Natalia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hiopiaevs8i8nhn1ak48lkgpqq